Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study

Published: Friday, May 30, 2014
Last Updated: Friday, May 30, 2014
Bookmark and Share
Company will present data from Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO.

4SC AG has announced positive top line data from its clinical Phase I TOPAS study with 4SC’s epigenetic cancer drug 4SC-202 in patients with advanced haematological tumours. 4SC-202, an oral small molecule inhibitor targeting WNT and Hedgehog (HH) signaling by specific inhibition of the epigenetic modifiers LSD1 and HDAC1, 2 and 3, was well tolerated, showed favorable pharmacokinetic properties and demonstrated promising signs of anti-tumour efficacy.

The main study phase has been completed for all patients, with one complete responder patient still remaining on follow-up study treatment. In detail, 4SC will present initial data from the study in a poster presentation at the upcoming annual ASCO (American Society of Clinical Oncology) meeting in Chicago.

The ASCO poster (Abstract No. 8559) will be available at when the presentation begins at 1:15 pm CDT (8:15 pm CEST) on 2 June 2014.

The first-in-man, open-label, dose-escalating, multi-centre, exploratory study evaluated safety, pharmacokinetics and pharmacodynamics of 4SC-202 in 24, heavily pre-treated, patients with advanced stages of haematological malignancies. The compound was studied in doses from 25 mg up to 400 mg total daily dose of 4SC-202 using various dosing schemes.

The drug showed promising signs of efficacy, both in terms of long-term disease stabilization of heavily pre-treated cancer patients and in terms of tumour shrinkage and objective radiological response. There was one complete remission (CR) and one partial remission (PR).

50% of patients (12 out of 24) had disease stabilization and time on study medication for more than 100 days, 13% were stabilized for over a year, and one patient could be stabilized for more than 2 years. The patient with the CR has been on the trial now for over 16 months, with both study treatment and CR still ongoing to date.

4SC-202 was generally safe and well tolerated in the doses tested. Due to the clean safety profile, no formal DLT (dose limiting toxicity) or MTD (maximum tolerated dose) could be determined. A recommended dose of 200 mg 4SC-202 once daily or twice daily in a 14+7 dosing scheme (14 days treatment, 7 days rest) was established.

The compound showed a favourable pharmacokinetic profile achieving potentially efficacious and well tolerated levels of 4SC-202 in patients. As for pharmacodynamics, the study showed promising biomarker responses including HDAC inhibition and a regulation of genes associated to the WNT signalling pathway in patient blood samples.

4SC will fully evaluate the data after final completion of the trial. In parallel, 4SC will investigate in particular WNT and HH related tumour indications for a possible Phase II development, and will also engage in talks with pharmaceutical partners interested in further development of the compound.

Enno Spillner, Chief Executive Officer of 4SC, said: “We are highly excited about the clinical Phase I top line results with our second epigenetic drug candidate 4SC-202. In the study 4SC-202 showed very good safety and highly promising signs of efficacy in heavily pre-treated patients with haematological tumours. We will now carry on our efforts on a Phase II development plan which we would like to pursue together with a potential pharmaceutical partner.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Receives Funding from the Eurostars Programme
Three-year research programme in cooperation with two other European epigenetics companies funded.
Saturday, October 03, 2015
4SC Strengthens Patent Protection for its Epigenetic Cancer Drug Candidate 4SC-202
A selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China.
Tuesday, August 18, 2015
4SC's Partner Yakult Honsha Starts Clinical Phase I Study in Pancreatic Tract Cancer Patients
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various dosing schemes in order to determine dose regimen for potential subsequent Phase II trials in advanced pancreatic and/or biliary tract cancer.
Friday, June 26, 2015
4SC Presents Final Results from Phase I AEGIS Trial at ASCO
Daily dosage of oral, anti-mitotic Eg5 inhibitor shows good safety and tolerability.
Thursday, June 04, 2015
BEYOND RESEARCH Initiative of 4SC Discovery and CRELUX Reaches First Milestone
Compounds for inhibiting oxygen radicals and associated signalling pathways optimized for developing innovative therapies for degenerative diseases.
Tuesday, January 13, 2015
4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205
4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucial role in cell division and tumour growth.
Friday, December 12, 2014
4SC's Partner Yakult Honsha Completes Phase I Part of Clinical Study with Resminostat in NSCLC Patients
Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian NSCLC patients.
Saturday, October 11, 2014
CRELUX and 4SC Discovery Awarded Research Grant
Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme.
Thursday, July 24, 2014
4SC Hires Experienced Pharmaceutical Manager and Oncology Expert
Dr Erich Enghofer joins 4SC in the newly created position of Executive Vice President.
Friday, July 04, 2014
4SC Discovery Receives EU Grant Worth EUR 450,000
Three-year research collaboration with the Medical Clinic of the University of Munich includes a project for identification and optimization of new compounds against a novel epigenetic target molecule.
Thursday, April 17, 2014
4SC Discovery Collaborates with Heidelberg University Hospital
The two-year R&D project is aimed at delivering a lead compound that can be brought to clinical development with the help of potential partners.
Friday, March 21, 2014
4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
4SC's Partner Yakult Honsha Starts Clinical Phase I/II Study with Resminostat in NSCLC
The Phase I/II study will investigate safety and efficacy of resminostat/docetaxel combination vs. docetaxel alone as a novel treatment option for patients with advanced, metastatic, or recurrent NSCLC.
Thursday, July 25, 2013
4SC Expands Patent Protection for Epigenetic Anti-Cancer Compound
4SC AG announced that the company has significantly expanded international patent protection for 4SC-202 in the USA, China and Hong Kong.
Monday, July 15, 2013
4SC Gives Update on the Clinical Development of its Lead Cancer Compound Resminostat
Data from completed Phase I part of SHORE study confirms the safety of the resminostat FOLFIRI combination and showing encouraging signs of clinical benefit
Thursday, May 30, 2013
Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos